Alexandra Zanin-Zhorov

Dr. Zanin-Zhorov is Senior Vice President of Translational Medicine at Équilibre Biopharmaceutical Corp. Prior to joining Équilibre, Dr. Zanin-Zhorov was a Vice President, Head of Immunology at KadmonHoldings, Inc.,where she established a new research group and managed activities across research, clinical, regulatory, and business development. Dr. Zanin-Zhorov led the successful bench-to-bedside development of the selective ROCK2 inhibitor, REZUROCK, for a variety of inflammatory and fibrotic diseases including Psoriasis, Idiopathic Pulmonary Fibrosis and significant contributed to the REZUROCK FDA approval for patients with chronic Graft Versus Host Disease.

Prior to Kadmon, Dr. Zanin-Zhorov was a postdoctoral fellow at NYU School of Medicine where she led research efforts in defining signaling pathways that control immune cell function during disease state. Over her research career in both academic and industrial settings, Dr. Zanin-Zhorov published more than 30 scientific papers in high-profile journals including Science, PNAS, JCO and she is a co-inventor on 13 patents.

Dr. Zanin-Zhorov holds a Ph.D. degree in Immunology from the Weizmann Institute of Science in Israel, Master’s degree in Tumor Immunology and B.Sc. degree from Life Sciences Faculty at Tel-Aviv University in Israel.